While much of the global technology conversation remains fixated on artificial intelligence and large language models, China has been quietly and aggressively building out its brain-computer interface (BCI) industry. From government-backed research initiatives to a growing roster of private startups, the country is positioning itself to become a dominant force in a field that could reshape medicine, defense, and human-machine interaction for decades to come.
As TechCrunch reported, China’s BCI sector has entered a new phase of acceleration, driven by coordinated state investment, a permissive regulatory environment for clinical trials, and a deep bench of neuroscience and engineering talent emerging from the country’s top universities. The pace of development has caught the attention of researchers and policymakers in the United States and Europe, who are increasingly aware that the competitive dynamics of BCI may mirror those of AI — with China moving faster than many Western observers expected.
A National Strategy Takes Shape
China’s push into brain-computer interfaces is not an accident of market forces. It is the product of deliberate industrial policy. The technology was highlighted in China’s 14th Five-Year Plan as a strategic frontier, and since then, funding has flowed from both central and provincial governments into BCI research labs and commercial ventures. Cities like Beijing, Shanghai, and Shenzhen have established dedicated BCI innovation zones, offering tax incentives, subsidized lab space, and streamlined approval processes for companies working in the field.
The Chinese Academy of Sciences (CAS) has been at the center of much of this work, coordinating research across multiple institutes and serving as a pipeline for talent and intellectual property that feeds into the private sector. Several of China’s most prominent BCI startups trace their origins to CAS-affiliated labs, and the relationship between state-funded research and commercial application remains far more tightly coupled in China than in most Western countries.
The Private Sector Responds
The commercial side of China’s BCI industry has grown rapidly. Companies like NeuroXess, based in Shanghai, and BrainCo, which maintains operations in both China and the United States, have made significant strides in developing both invasive and non-invasive BCI devices. NeuroXess, for instance, has developed flexible electrode arrays designed for long-term implantation in the brain, and the company has conducted animal trials that it says demonstrate the viability of its approach for treating neurological conditions such as epilepsy and paralysis.
BrainCo, meanwhile, has focused heavily on non-invasive applications, including prosthetic limbs controlled by neural signals and educational tools that claim to monitor and enhance student concentration. The company’s prosthetic hand, which uses electromyography and machine learning to interpret signals from residual limb muscles, has been deployed in several countries and represents one of the most commercially advanced BCI-adjacent products to come out of China. According to TechCrunch, the number of BCI-related patent filings in China has surged in recent years, with the country now rivaling the United States in total filings — a metric that, while imperfect, signals the breadth of research and development activity underway.
Clinical Trials and the Regulatory Advantage
One of the most significant factors in China’s BCI acceleration is its regulatory framework — or, more precisely, the relative speed with which clinical trials can be initiated and conducted. In the United States, the Food and Drug Administration has maintained a cautious approach to implantable neural devices, requiring extensive preclinical data and multi-phase trials before any device can be approved for human use. Neuralink, Elon Musk’s high-profile BCI company, received FDA approval for its first human trial only in 2023, after years of regulatory back-and-forth.
In China, the approval timeline for similar trials has been considerably shorter. Chinese hospitals and research institutions have initiated human trials of implantable BCI devices with what Western regulators might consider limited preclinical evidence. This is not necessarily a criticism — proponents argue that faster trials mean faster learning and faster iteration — but it does raise questions about patient safety and informed consent that have not been fully addressed in the public discourse. The speed, however, is undeniable: multiple Chinese institutions have now implanted BCI devices in human patients, and early results from these trials are beginning to appear in peer-reviewed journals.
The Military Dimension
No discussion of China’s BCI ambitions would be complete without acknowledging the military implications. The People’s Liberation Army (PLA) has funded research into brain-computer interfaces for applications ranging from enhanced pilot cognition to direct neural control of unmanned systems. While much of this work remains classified, open-source publications from PLA-affiliated research institutes have described experiments in which human operators used non-invasive BCI headsets to control drones and robotic vehicles.
The dual-use nature of BCI technology — its applicability to both medical and military purposes — has drawn scrutiny from U.S. defense officials. The Defense Advanced Research Projects Agency (DARPA) has its own long-running BCI programs, but some analysts have expressed concern that China’s civil-military fusion strategy gives it an inherent advantage in translating academic research into defense applications. Under this model, there is no clear boundary between civilian and military research, and companies that receive government BCI funding may be expected to share their findings with defense agencies.
Where the U.S. Stands — and Where It Lags
The United States remains home to some of the world’s leading BCI researchers and companies. Neuralink has dominated headlines with its implantable chip, the N1, which has now been placed in a small number of human patients with promising early results. Synchron, an Australian-American company, has taken a different approach with its Stentrode device, which is implanted via blood vessels rather than through open brain surgery, reducing surgical risk. Blackrock Neurotech, based in Utah, has decades of experience with implantable electrode arrays and has supplied hardware for many of the foundational BCI studies conducted in the U.S.
But the American BCI industry faces headwinds that its Chinese counterparts do not. Regulatory timelines remain long. Venture capital funding, while substantial, is subject to the cyclical enthusiasm of investors who may lose patience with the multi-year development timelines inherent in medical device work. And the fragmented nature of the U.S. research funding system — split among the National Institutes of Health, DARPA, the National Science Foundation, and private foundations — can make it difficult to coordinate the kind of sustained, multi-institutional effort that China’s centralized model facilitates.
Ethical Questions Loom Large
The rapid expansion of BCI technology in China has raised ethical concerns that extend beyond patient safety in clinical trials. Privacy advocates have flagged the potential for neural data — information derived directly from brain activity — to be collected, stored, and analyzed by state actors. In a country where mass surveillance is already pervasive, the prospect of technology that can decode aspects of thought and intention from neural signals is particularly fraught.
Chinese BCI companies have generally not engaged in detailed public discussion of these issues, and China’s data protection laws, while they have been strengthened in recent years, contain broad national security exceptions that could allow government access to neural data. Western researchers have called for international norms governing the collection and use of brain data, but progress toward any binding framework has been slow. The NeuroRights Foundation, a U.S.-based advocacy group, has pushed for constitutional protections for cognitive liberty in several countries, but China has not participated in these discussions.
What Comes Next for the Global BCI Race
The trajectory of China’s BCI industry suggests that the gap between Chinese and Western capabilities will continue to narrow — and may, in some areas, reverse entirely. China’s advantages in manufacturing, its willingness to move quickly on clinical trials, and its coordinated state funding model give it structural advantages that are difficult for market-driven Western economies to replicate.
At the same time, the quality and openness of China’s BCI research remains uneven. Peer review standards vary, and some Western scientists have expressed skepticism about the reproducibility of results published by Chinese BCI labs. The long-term success of any BCI program will depend not just on speed but on the reliability and safety of the devices produced — metrics that take years to establish.
For now, the global BCI race is intensifying. As TechCrunch noted, the sheer volume of activity in China — the number of companies, the scale of government investment, the pace of clinical trials — has created a momentum that is difficult to ignore. Whether that momentum translates into durable technological leadership will depend on choices made not just in Beijing and Shanghai, but in Washington, Brussels, and research universities around the world. The stakes, measured in both human health and geopolitical influence, could hardly be higher.